You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePravastatin
Accession NumberDB00175  (APRD00328)
TypeSmall Molecule
GroupsApproved
DescriptionPravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.
Structure
Thumb
Synonyms
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
Pravastatin acid
Pravastatina
Pravastatine
Pravastatinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-pravastatintablet40 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-pravastatintablet10 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-pravastatintablet20 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Act Pravastatintablet20 mgoralActavis Pharma Company2003-12-09Not applicableCanada
Act Pravastatintablet40 mgoralActavis Pharma Company2003-12-09Not applicableCanada
Act Pravastatintablet10 mgoralActavis Pharma Company2003-12-09Not applicableCanada
Ava-pravastatintablet20 mgoralAvanstra Inc2011-10-112011-12-12Canada
Ava-pravastatintablet40 mgoralAvanstra Inc2011-10-112011-12-12Canada
Ava-pravastatintablet10 mgoralAvanstra Inc2011-10-112011-12-12Canada
Bio Pravastatintablet10 mgoralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio Pravastatintablet20 mgoralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio Pravastatintablet40 mgoralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio-pravastatintablet40 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-pravastatintablet20 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-pravastatintablet10 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-pravastatintablet20 mgoralDominion Pharmacal2004-05-12Not applicableCanada
Dom-pravastatintablet40 mgoralDominion Pharmacal2004-05-12Not applicableCanada
Dom-pravastatintablet10 mgoralDominion Pharmacal2004-05-12Not applicableCanada
Ipg-pravastatintablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-pravastatintablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-pravastatintablet40 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-pravastatintablet10 mgoralJamp Pharma Corporation2010-04-01Not applicableCanada
Jamp-pravastatintablet20 mgoralJamp Pharma Corporation2010-04-01Not applicableCanada
Jamp-pravastatintablet40 mgoralJamp Pharma Corporation2010-04-01Not applicableCanada
Lin-pravastatintablet10 mgoralLinson Pharma Co.2000-07-132006-05-29Canada
Lin-pravastatintablet20 mgoralLinson Pharma Co.2000-07-132006-05-29Canada
Lin-pravastatintablet40 mgoralLinson Pharma Co.2000-07-132006-05-29Canada
Mar-pravastatintablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pravastatintablet40 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pravastatintablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pravastatintablet20 mgoralMint Pharmaceuticals Inc2009-02-06Not applicableCanada
Mint-pravastatintablet40 mgoralMint Pharmaceuticals Inc2009-02-06Not applicableCanada
Mint-pravastatintablet10 mgoralMint Pharmaceuticals Inc2009-02-06Not applicableCanada
Mylan-pravastatintablet40 mgoralMylan Pharmaceuticals Ulc2005-04-07Not applicableCanada
Mylan-pravastatintablet10 mgoralMylan Pharmaceuticals Ulc2005-04-07Not applicableCanada
Mylan-pravastatintablet20 mgoralMylan Pharmaceuticals Ulc2005-04-07Not applicableCanada
Ntp-pravastatintablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-pravastatintablet20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-pravastatintablet40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-pravastatin Tabletstablet20 mgoralNu Pharm Inc2002-05-022012-09-04Canada
Nu-pravastatin Tabletstablet40 mgoralNu Pharm Inc2002-05-162012-09-04Canada
Nu-pravastatin Tabletstablet10 mgoralNu Pharm Inc2002-05-132012-09-04Canada
Pendo-pravastatintablet10 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Pendo-pravastatintablet20 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-pravastatintablet10 mgoralPharmascience Inc2003-07-21Not applicableCanada
PMS-pravastatintablet20 mgoralPharmascience Inc2003-07-21Not applicableCanada
PMS-pravastatintablet40 mgoralPharmascience Inc2003-07-21Not applicableCanada
Pravacholtablet20 mg/1oralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Pravacholtablet40 mg/1oralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Pravacholtablet80 mg/1oralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Pravacholtablet80 mgoralBristol Myers Squibb CanadaNot applicableNot applicableCanada
Pravachol - Tab 10mgtablet10 mgoralBristol Myers Squibb Canada1990-12-31Not applicableCanada
Pravachol - Tab 20mgtablet20 mgoralBristol Myers Squibb Canada1990-12-31Not applicableCanada
Pravachol - Tab 40mgtablet40 mgoralBristol Myers Squibb Canada1996-08-21Not applicableCanada
Pravastatintablet20 mgoralSanis Health Inc2010-11-23Not applicableCanada
Pravastatintablet10 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Pravastatintablet40 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pravastatintablet40 mgoralSivem Pharmaceuticals Ulc2012-07-23Not applicableCanada
Pravastatintablet40 mgoralMeliapharm Inc2004-07-222014-06-25Canada
Pravastatintablet40 mgoralSanis Health Inc2010-12-01Not applicableCanada
Pravastatintablet20 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Pravastatintablet10 mgoralSivem Pharmaceuticals Ulc2012-07-23Not applicableCanada
Pravastatintablet10 mgoralMeliapharm Inc2004-07-222014-06-25Canada
Pravastatintablet40 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Pravastatintablet10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pravastatintablet10 mgoralSanis Health Inc2010-11-23Not applicableCanada
Pravastatintablet20 mgoralSivem Pharmaceuticals Ulc2012-07-23Not applicableCanada
Pravastatintablet20 mgoralMeliapharm Inc2004-07-222014-06-25Canada
Pravastatintablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pravastatin Tabletstablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pravastatin Tabletstablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pravastatin Tabletstablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pravastatin-10tablet10 mgoralPro Doc Limitee2002-12-23Not applicableCanada
Pravastatin-20tablet20 mgoralPro Doc Limitee2002-12-23Not applicableCanada
Pravastatin-40tablet40 mgoralPro Doc Limitee2002-12-23Not applicableCanada
Priva-pravastatintablet20 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-pravastatintablet40 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-pravastatintablet10 mgoralPharmapar IncNot applicableNot applicableCanada
Q-pravastatintablet10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-pravastatintablet20 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-pravastatintablet40 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-pravastatintablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-05-16Not applicableCanada
Ran-pravastatintablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-05-16Not applicableCanada
Ran-pravastatintablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-05-16Not applicableCanada
Ratio-pravastatintablet20 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-02-032014-09-19Canada
Ratio-pravastatintablet40 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-02-032014-09-19Canada
Ratio-pravastatintablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-02-032014-09-19Canada
Riva-pravastatintablet10 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-pravastatintablet10 mgoralLaboratoire Riva Inc2005-10-28Not applicableCanada
Riva-pravastatintablet10 mgoralLaboratoire Riva Inc2004-10-222005-06-30Canada
Riva-pravastatintablet20 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-pravastatintablet20 mgoralLaboratoire Riva Inc2005-10-28Not applicableCanada
Riva-pravastatintablet20 mgoralLaboratoire Riva Inc2004-10-222005-06-30Canada
Riva-pravastatintablet40 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-pravastatintablet40 mgoralLaboratoire Riva Inc2005-10-28Not applicableCanada
Riva-pravastatintablet40 mgoralLaboratoire Riva Inc2004-10-222005-06-30Canada
Sandoz Pravastatintablet10 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Pravastatintablet10 mgoralSandoz Canada Incorporated2003-12-08Not applicableCanada
Sandoz Pravastatintablet20 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Pravastatintablet20 mgoralSandoz Canada Incorporated2003-08-12Not applicableCanada
Sandoz Pravastatintablet40 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Pravastatintablet40 mgoralSandoz Canada Incorporated2003-08-12Not applicableCanada
Teva-pravastatintablet40 mgoralTeva Canada Limited2003-01-08Not applicableCanada
Teva-pravastatintablet10 mgoralTeva Canada Limited2003-01-08Not applicableCanada
Teva-pravastatintablet20 mgoralTeva Canada Limited2003-01-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pravastatintablet10 mgoralApotex Inc2001-02-27Not applicableCanada
Apo-pravastatintablet20 mgoralApotex Inc2001-02-27Not applicableCanada
Apo-pravastatintablet40 mgoralApotex Inc2001-02-27Not applicableCanada
Pravastatintablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2011-09-20Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMajor Pharmaceuticals2010-07-06Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralAmerican Health Packaging2011-10-01Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-12-28Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralPhysicians Total Care, Inc.2007-01-25Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralRebel Distributors Corp2006-10-23Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralTeva Pharmaceuticals USA Inc2006-04-25Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-31Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-12Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralSandoz Inc2014-04-28Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralbryant ranch prepack2006-10-23Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAv Pak2016-03-15Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2010-07-06Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-09-29Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMylan Institutional Inc.2006-05-22Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralDIRECT RX2015-12-28Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralBlenheim Pharmacal, Inc.2012-02-13Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralSt Marys Medical Park Pharmacy2013-08-14Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMajor Pharmaceuticals2008-08-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-05-11Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2014-10-03Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralInternational Laboratories, Inc.2008-03-27Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2013-05-24Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAidarex Pharmaceuticals LLC2010-03-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Inc.2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralREMEDYREPACK INC.2013-07-012016-04-05Us
Pravastatin Sodiumtablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-07-22Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralREMEDYREPACK INC.2011-11-17Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMajor Pharmaceuticals2010-07-06Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAmerican Health Packaging2011-10-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-07Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPhysicians Total Care, Inc.2006-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCardinal Health2008-08-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralRebel Distributors Corp2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralTeva Pharmaceuticals USA Inc2006-04-25Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-31Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2013-05-232016-04-05Us
Pravastatin Sodiumtablet20 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralSandoz Inc2014-04-28Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralbryant ranch prepack2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralUnit Dose Services2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralInternational Laboratories, Inc.2015-05-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralProficient Rx LP2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralActavis Pharma, Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-04-28Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMylan Institutional Inc.2007-10-03Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Llc2006-04-25Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2013-11-052016-04-05Us
Pravastatin Sodiumtablet40 mg/1oralSt Marys Medical Park Pharmacy2013-08-14Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMajor Pharmaceuticals2008-08-01Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2015-12-08Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralInternational Laboratories, Inc.2009-02-09Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCardinal Health2013-05-24Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralAidarex Pharmaceuticals LLC2010-03-30Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralPhysicians Total Care, Inc.2006-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralRebel Distributors Corp2007-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-07-22Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2011-11-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2015-12-10Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralBlenheim Pharmacal, Inc.2014-02-19Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAmerican Health Packaging2011-10-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMc Kesson Contract Packaging2013-04-12Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralInternational Laboratories, Inc.2015-05-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2007-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralRebel Distributors Corp2006-10-23Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralTeva Pharmaceuticals USA Inc2006-04-25Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2013-05-232016-04-05Us
Pravastatin Sodiumtablet40 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralSandoz Inc2014-07-28Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCardinal Health2012-02-10Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-04-28Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-12Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralProficient Rx LP2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralActavis Pharma, Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2011-06-08Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2014-10-03Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralMajor Pharmaceuticals2010-07-06Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMed Vantx, Inc.2006-04-25Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-05-11Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralInternational Laboratories, Inc.2013-04-26Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCardinal Health2013-05-24Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-18Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralPhysicians Total Care, Inc.2009-12-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralRebel Distributors Corp2007-05-11Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralUnit Dose Services2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralDIRECT RX2015-12-28Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralBlenheim Pharmacal, Inc.2012-02-13Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralAmerican Health Packaging2014-05-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCobalt Laboratories Inc.2006-10-232015-12-29Us
Pravastatin Sodiumtablet80 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2012-02-10Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralInternational Labs, Inc.2012-02-20Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCardinal Health2007-05-11Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAidarex Pharmaceuticals LLC2010-03-30Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralTeva Pharmaceuticals USA Inc2008-09-29Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2013-07-01Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralMajor Pharmaceuticals2008-08-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralSandoz Inc2014-04-28Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNorthwind Pharmaceuticals, LLC2014-07-10Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralbryant ranch prepack2006-10-23Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralActavis Pharma, Inc.2007-12-28Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralAv Pak2016-03-15Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ElisorNot Available
LipostatNot Available
MevalotinNot Available
PravaselectNot Available
SelipranNot Available
Brand mixtures
NameLabellerIngredients
Pal-pravastatin-asaPaladin Labs Inc
Salts
Name/CASStructureProperties
Pravastatin Sodium
Thumb
  • InChI Key: VWBQYTRBTXKKOG-NJUCWUMRNA-M
  • Monoisotopic Mass: 446.228048149
  • Average Mass: 446.5096
DBSALT000146
Categories
UNIIKXO2KT9N0G
CAS number81093-37-0
WeightAverage: 424.5277
Monoisotopic: 424.246103506
Chemical FormulaC23H36O7
InChI KeyInChIKey=TUZYXOIXSAXUGO-PZAWKZKUSA-N
InChI
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
IUPAC Name
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
SMILES
[H][C@]12[[email protected]](C[[email protected]](O)C=C1C=C[[email protected]](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbocyclic fatty acids. These are fatty acids containing a carbocylic ring .
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassFatty acids and conjugates
Direct ParentCarbocyclic fatty acids
Alternative Parents
Substituents
  • Medium-chain hydroxy acid
  • Fatty alcohol
  • Carbocyclic fatty acid
  • Medium-chain fatty acid
  • Fatty acid ester
  • Branched fatty acid
  • Beta-hydroxy acid
  • Hydroxy acid
  • Dicarboxylic acid or derivatives
  • Secondary alcohol
  • Carboxylic acid ester
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
PharmacodynamicsThe primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.
Mechanism of actionPravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.
Related Articles
AbsorptionPravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.
Volume of distributionNot Available
Protein binding50% bound to human plasma proteins.
Metabolism

Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3α-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.

Route of eliminationApproximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.
Half life77 hours
ClearanceNot Available
ToxicitySide effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD50= 12,000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pravastatin Action PathwayDrug actionSMP00089
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Kinesin-like protein KIF6
Gene symbol: KIF6
UniProt: Q6ZMV9
rs20455 Not AvailableC AlleleImproved response to statin drugs18222353
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Gene symbol: HMGCR
UniProt: P04035
rs17244841 Not AvailableT AlleleReduced response to statin drugs15199031
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb
  • Apotex corp
  • Dr reddys laboratories inc
  • Glenmark generics ltd
  • Lek pharmaceuticals dd
  • Lupin pharmaceuticals inc
  • Matrix laboratories ltd
  • Mylan pharmaceuticals inc
  • Pliva hrvatska doo
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tablet (delayed-release); kit; tabletoral
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Tabletoral80 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral40 mg
Tabletoral10 mg/1
Prices
Unit descriptionCostUnit
Pravachol 40 mg tablet6.53USD tablet
Pravachol 80 mg tablet6.53USD tablet
Pravastatin sodium 40 mg tablet4.89USD tablet
Pravastatin sodium 80 mg tablet4.89USD tablet
Pravachol 20 mg tablet4.39USD tablet
Pravachol 10 mg tablet4.38USD tablet
Pravastatin sodium 20 mg tablet3.33USD tablet
Pravastatin sodium 10 mg tablet3.28USD tablet
Apo-Pravastatin 40 mg Tablet1.42USD tablet
Co Pravastatin 40 mg Tablet1.42USD tablet
Jamp-Pravastatin 40 mg Tablet1.42USD tablet
Mint-Pravastatin 40 mg Tablet1.42USD tablet
Mylan-Pravastatin 40 mg Tablet1.42USD tablet
Novo-Pravastatin 40 mg Tablet1.42USD tablet
Pms-Pravastatin 40 mg Tablet1.42USD tablet
Pravachol 40 mg Tablet1.42USD tablet
Ran-Pravastatin 40 mg Tablet1.42USD tablet
Ratio-Pravastatin 40 mg Tablet1.42USD tablet
Sandoz Pravastatin 40 mg Tablet1.42USD tablet
Apo-Pravastatin 20 mg Tablet1.18USD tablet
Co Pravastatin 20 mg Tablet1.18USD tablet
Jamp-Pravastatin 20 mg Tablet1.18USD tablet
Mint-Pravastatin 20 mg Tablet1.18USD tablet
Mylan-Pravastatin 20 mg Tablet1.18USD tablet
Novo-Pravastatin 20 mg Tablet1.18USD tablet
Pms-Pravastatin 20 mg Tablet1.18USD tablet
Pravachol 20 mg Tablet1.18USD tablet
Ran-Pravastatin 20 mg Tablet1.18USD tablet
Ratio-Pravastatin 20 mg Tablet1.18USD tablet
Sandoz Pravastatin 20 mg Tablet1.18USD tablet
Apo-Pravastatin 10 mg Tablet1.0USD tablet
Co Pravastatin 10 mg Tablet1.0USD tablet
Jamp-Pravastatin 10 mg Tablet1.0USD tablet
Mint-Pravastatin 10 mg Tablet1.0USD tablet
Mylan-Pravastatin 10 mg Tablet1.0USD tablet
Novo-Pravastatin 10 mg Tablet1.0USD tablet
Pms-Pravastatin 10 mg Tablet1.0USD tablet
Pravachol 10 mg Tablet1.0USD tablet
Ran-Pravastatin 10 mg Tablet1.0USD tablet
Ratio-Pravastatin 10 mg Tablet1.0USD tablet
Sandoz Pravastatin 10 mg Tablet1.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1323836 No1993-11-022010-11-02Canada
US5622985 No1994-10-222014-10-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point171.2 - 173°CMSDS
water solubilitySoluble FDA label
logP0.59 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.242 mg/mLALOGPS
logP2.23ALOGPS
logP1.65ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.21ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.29 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity113.6 m3·mol-1ChemAxon
Polarizability46.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, “Method for producing pravastatin precursor, ML-236B.” U.S. Patent US6204032, issued October, 1976.

US6204032
General ReferencesNot Available
External Links
ATC CodesC10AA03C10BX02C10BA03
AHFS Codes
  • 24:06.08
PDB EntriesNot Available
FDA labelDownload (145 KB)
MSDSDownload (44 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of Pravastatin can be decreased when combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Pravastatin.
AcenocoumarolPravastatin may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Pravastatin can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Pravastatin.
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Pravastatin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Pravastatin.
AlbendazoleThe serum concentration of Pravastatin can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Pravastatin can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Pravastatin.
AlectinibThe serum concentration of Pravastatin can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Pravastatin can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Pravastatin.
Aluminum hydroxideThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum phosphate.
AmantadineThe serum concentration of Pravastatin can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Pravastatin.
Aminohippuric acidThe serum concentration of Pravastatin can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Pravastatin can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Pravastatin can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Pravastatin can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Pravastatin.
AmprenavirThe serum concentration of Pravastatin can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Pravastatin can be increased when it is combined with Amsacrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Pravastatin.
AprepitantThe serum concentration of Pravastatin can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Pravastatin.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Pravastatin.
AstemizoleThe serum concentration of Pravastatin can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Pravastatin.
AtenololThe serum concentration of Pravastatin can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Pravastatin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Pravastatin can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Pravastatin.
AzelastineThe serum concentration of Pravastatin can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Pravastatin can be increased when it is combined with Azithromycin.
BenzocaineThe serum concentration of Pravastatin can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Pravastatin can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Pravastatin.
BexaroteneThe serum concentration of Pravastatin can be decreased when it is combined with Bexarotene.
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin.
BiperidenThe serum concentration of Pravastatin can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe serum concentration of Pravastatin can be decreased when it is combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Pravastatin can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Pravastatin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Pravastatin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Pravastatin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin.
BromocriptineThe serum concentration of Pravastatin can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Pravastatin can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Pravastatin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Pravastatin.
CaffeineThe serum concentration of Pravastatin can be increased when it is combined with Caffeine.
Calcium carbonateThe serum concentration of Pravastatin can be decreased when it is combined with Calcium carbonate.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Pravastatin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Pravastatin.
CandesartanThe serum concentration of Pravastatin can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Pravastatin can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Pravastatin can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Pravastatin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Pravastatin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Pravastatin.
CarvedilolThe serum concentration of Pravastatin can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Pravastatin can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Pravastatin can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Pravastatin.
ChloroquineThe serum concentration of Pravastatin can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Pravastatin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Pravastatin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Pravastatin can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Pravastatin can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Pravastatin can be increased when it is combined with Cholesterol.
CholestyramineThe serum concentration of Pravastatin can be decreased when it is combined with Cholestyramine.
Cholic AcidThe serum concentration of Pravastatin can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Pravastatin can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Pravastatin can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Pravastatin.
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Pravastatin.
CiprofloxacinThe serum concentration of Pravastatin can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Pravastatin.
CitalopramThe serum concentration of Pravastatin can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Pravastatin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Pravastatin can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Pravastatin.
ClofazimineThe serum concentration of Pravastatin can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Pravastatin.
ClomipramineThe serum concentration of Pravastatin can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Pravastatin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Pravastatin.
ClotrimazoleThe metabolism of Pravastatin can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Pravastatin.
CobicistatThe serum concentration of Pravastatin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Pravastatin.
ColchicineThe serum concentration of Pravastatin can be increased when it is combined with Colchicine.
ColesevelamThe serum concentration of Pravastatin can be decreased when it is combined with Colesevelam.
ColestipolThe serum concentration of Pravastatin can be decreased when it is combined with Colestipol.
ColforsinThe serum concentration of Pravastatin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Pravastatin can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pravastatin.
CrizotinibThe metabolism of Pravastatin can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Pravastatin.
CyclophosphamideThe serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Pravastatin can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Pravastatin.
Cyproterone acetateThe serum concentration of Pravastatin can be increased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Pravastatin.
DabrafenibThe serum concentration of Pravastatin can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Pravastatin.
DaclatasvirThe serum concentration of Pravastatin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Pravastatin can be increased when it is combined with Dactinomycin.
DanazolThe serum concentration of Pravastatin can be increased when it is combined with Danazol.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Pravastatin.
DaptomycinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin.
DarunavirThe serum concentration of Pravastatin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Pravastatin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Pravastatin can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Pravastatin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Pravastatin.
DeferasiroxThe serum concentration of Pravastatin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Pravastatin can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Pravastatin can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Pravastatin can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Pravastatin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Pravastatin.
DextromethorphanThe serum concentration of Pravastatin can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Pravastatin.
DiclofenacThe serum concentration of Pravastatin can be increased when it is combined with Diclofenac.
DicoumarolPravastatin may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pravastatin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Pravastatin.
DigoxinThe serum concentration of Pravastatin can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pravastatin.
DihydroergotamineThe metabolism of Pravastatin can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Pravastatin.
DiltiazemThe metabolism of Pravastatin can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Pravastatin.
DipyridamoleThe serum concentration of Pravastatin can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Pravastatin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Pravastatin.
DoxazosinThe serum concentration of Pravastatin can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Pravastatin can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Pravastatin can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Pravastatin.
DoxycyclineThe metabolism of Pravastatin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Pravastatin can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Pravastatin can be decreased when combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Pravastatin.
EfavirenzThe serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Pravastatin can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Pravastatin.
EltrombopagThe serum concentration of Pravastatin can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Pravastatin can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Pravastatin can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Pravastatin.
ErgonovineThe serum concentration of Pravastatin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Pravastatin can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Pravastatin.
ErythromycinThe serum concentration of Pravastatin can be increased when it is combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Pravastatin can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Pravastatin.
EstramustineThe serum concentration of Pravastatin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Pravastatin can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Pravastatin.
EstroneThe serum concentration of Pravastatin can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Pravastatin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pravastatin.
Ethyl biscoumacetatePravastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
EtoposideThe serum concentration of Pravastatin can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Pravastatin can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Pravastatin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Pravastatin.
FelodipineThe serum concentration of Pravastatin can be increased when it is combined with Felodipine.
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Pravastatin.
FentanylThe serum concentration of Pravastatin can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin.
FexofenadineThe serum concentration of Pravastatin can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Pravastatin.
FloxuridineThe metabolism of Pravastatin can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Pravastatin can be decreased when combined with Fluconazole.
FluorouracilThe metabolism of Pravastatin can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Pravastatin can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Pravastatin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Pravastatin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Pravastatin can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Pravastatin.
FluvastatinThe metabolism of Pravastatin can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Pravastatin can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Pravastatin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pravastatin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Pravastatin can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Pravastatin can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Pravastatin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Pravastatin.
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Pravastatin.
GenisteinThe serum concentration of Pravastatin can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Pravastatin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Pravastatin can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Pravastatin can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Pravastatin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Pravastatin.
HaloperidolThe serum concentration of Pravastatin can be increased when it is combined with Haloperidol.
HydrocortisoneThe serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Pravastatin.
IdelalisibThe serum concentration of Pravastatin can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Pravastatin can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Pravastatin.
ImipramineThe serum concentration of Pravastatin can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Pravastatin.
IndinavirThe serum concentration of Pravastatin can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Pravastatin.
IndomethacinThe serum concentration of Pravastatin can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Pravastatin can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Pravastatin.
IsavuconazoniumThe metabolism of Pravastatin can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Pravastatin can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Pravastatin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Pravastatin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Pravastatin can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Pravastatin can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Pravastatin.
KetoconazoleThe serum concentration of Pravastatin can be increased when it is combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Pravastatin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Pravastatin.
LansoprazoleThe serum concentration of Pravastatin can be increased when it is combined with Lansoprazole.
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Pravastatin.
LapatinibThe serum concentration of Pravastatin can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Pravastatin.
LeflunomideThe metabolism of Pravastatin can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Pravastatin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Pravastatin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Pravastatin.
LevofloxacinThe serum concentration of Pravastatin can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Pravastatin.
LevothyroxineThe serum concentration of Pravastatin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Pravastatin can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Pravastatin.
LiothyronineThe serum concentration of Pravastatin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Pravastatin can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Pravastatin can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Pravastatin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Pravastatin can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Pravastatin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Pravastatin can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Pravastatin can be increased when it is combined with Losartan.
LovastatinThe metabolism of Pravastatin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Pravastatin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pravastatin can be decreased when it is combined with Lumacaftor.
MagaldrateThe serum concentration of Pravastatin can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.
Magnesium TrisilicateThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium Trisilicate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Pravastatin.
MaprotilineThe serum concentration of Pravastatin can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Pravastatin can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Pravastatin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Pravastatin can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Pravastatin can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Pravastatin can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pravastatin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Pravastatin.
MetoprololThe serum concentration of Pravastatin can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Pravastatin can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Pravastatin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Pravastatin can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Pravastatin.
MifepristoneThe metabolism of Pravastatin can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Pravastatin.
MitomycinThe serum concentration of Pravastatin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Pravastatin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Pravastatin can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Pravastatin.
ModafinilThe serum concentration of Pravastatin can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Pravastatin can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pravastatin.
NadololThe serum concentration of Nadolol can be increased when it is combined with Pravastatin.
NafcillinThe serum concentration of Pravastatin can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Pravastatin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Pravastatin.
NaltrexoneThe serum concentration of Pravastatin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Pravastatin can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Pravastatin can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Pravastatin.
NeostigmineThe serum concentration of Pravastatin can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Pravastatin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Pravastatin can be decreased when combined with Nevirapine.
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Pravastatin.
NicardipineThe serum concentration of Pravastatin can be increased when it is combined with Nicardipine.
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Pravastatin.
NifedipineThe serum concentration of Pravastatin can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Pravastatin.
NilotinibThe metabolism of Pravastatin can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Pravastatin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Pravastatin.
NisoldipineThe serum concentration of Pravastatin can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Pravastatin can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Pravastatin.
NorethisteroneThe serum concentration of Pravastatin can be decreased when it is combined with Norethisterone.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Pravastatin.
OlaparibThe metabolism of Pravastatin can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Pravastatin.
OmeprazoleThe serum concentration of Pravastatin can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Pravastatin can be increased when it is combined with Osimertinib.
P-NitrophenolThe serum concentration of Pravastatin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Pravastatin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Pravastatin can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Pravastatin can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Pravastatin.
PantoprazoleThe serum concentration of Pravastatin can be increased when it is combined with Pantoprazole.
ParoxetineThe risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.
ParoxetineThe serum concentration of Pravastatin can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Pravastatin.
PentobarbitalThe metabolism of Pravastatin can be increased when combined with Pentobarbital.
PerindoprilThe serum concentration of Pravastatin can be increased when it is combined with Perindopril.
PhenindionePravastatin may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Pravastatin can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Pravastatin.
PhenprocoumonPravastatin may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Pravastatin can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pravastatin.
PimozideThe serum concentration of Pravastatin can be increased when it is combined with Pimozide.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Pravastatin.
Platelet Activating FactorThe serum concentration of Pravastatin can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Pravastatin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Pravastatin.
PosaconazoleThe serum concentration of Pravastatin can be increased when it is combined with Posaconazole.
PrazosinThe serum concentration of Pravastatin can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Pravastatin.
PrednisoneThe serum concentration of Pravastatin can be increased when it is combined with Prednisone.
PrimidoneThe metabolism of Pravastatin can be increased when combined with Primidone.
ProbenecidThe serum concentration of Pravastatin can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Pravastatin can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Pravastatin.
PromethazineThe serum concentration of Pravastatin can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Pravastatin can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Pravastatin can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Pravastatin can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Pravastatin.
PyrimethamineThe metabolism of Pravastatin can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Pravastatin can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Pravastatin.
QuinacrineThe serum concentration of Pravastatin can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Pravastatin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Pravastatin can be increased when it is combined with Quinine.
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Pravastatin.
RanitidineThe serum concentration of Pravastatin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Pravastatin.
ReboxetineThe serum concentration of Pravastatin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Pravastatin can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Pravastatin can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Pravastatin.
RifabutinThe metabolism of Pravastatin can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Pravastatin can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Pravastatin.
RifapentineThe metabolism of Pravastatin can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pravastatin.
RilpivirineThe serum concentration of Pravastatin can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Pravastatin.
RitonavirThe serum concentration of Pravastatin can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Pravastatin.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Pravastatin.
RolapitantThe serum concentration of Pravastatin can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Pravastatin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Pravastatin.
SaquinavirThe serum concentration of Pravastatin can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Pravastatin.
ScopolamineThe serum concentration of Pravastatin can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Pravastatin can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Pravastatin can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Pravastatin.
SertralineThe serum concentration of Pravastatin can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Pravastatin can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Pravastatin.
SiltuximabThe serum concentration of Pravastatin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pravastatin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Pravastatin can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Pravastatin can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Pravastatin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Pravastatin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Pravastatin.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Pravastatin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Pravastatin.
SpironolactoneThe serum concentration of Pravastatin can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Pravastatin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Pravastatin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Pravastatin can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Pravastatin can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Pravastatin can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Pravastatin can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Pravastatin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Pravastatin can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Pravastatin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Pravastatin can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Pravastatin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Pravastatin can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Pravastatin.
TamoxifenThe serum concentration of Pravastatin can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Pravastatin.
Taurocholic AcidThe serum concentration of Pravastatin can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pravastatin.
TelaprevirThe serum concentration of Pravastatin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Pravastatin can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Pravastatin can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Pravastatin.
TerazosinThe serum concentration of Pravastatin can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Pravastatin can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Pravastatin can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Pravastatin can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Pravastatin can be increased when it is combined with Testosterone.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pravastatin.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Pravastatin.
TiclopidineThe metabolism of Pravastatin can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Pravastatin.
TocilizumabThe serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Pravastatin can be decreased when combined with Tolbutamide.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Pravastatin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Pravastatin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Pravastatin.
TrabectedinPravastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Pravastatin.
TrazodoneThe serum concentration of Pravastatin can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Pravastatin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Pravastatin can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Pravastatin can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Pravastatin can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Pravastatin can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Pravastatin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Pravastatin.
Valproic AcidThe metabolism of Pravastatin can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Pravastatin can be decreased when combined with Valsartan.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Pravastatin.
VenlafaxineThe metabolism of Pravastatin can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Pravastatin.
VerapamilThe metabolism of Pravastatin can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Pravastatin.
VinblastineThe serum concentration of Pravastatin can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Pravastatin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Pravastatin.
VincristineThe serum concentration of Pravastatin can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Pravastatin can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Pravastatin.
VoriconazoleThe metabolism of Pravastatin can be decreased when combined with Voriconazole.
WarfarinPravastatin may increase the anticoagulant activities of Warfarin.
ZafirlukastThe metabolism of Pravastatin can be decreased when combined with Zafirlukast.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Pravastatin.
ZimelidineThe serum concentration of Pravastatin can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Pravastatin can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.
Gene Name:
HMGCR
Uniprot ID:
P04035
Molecular Weight:
97475.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
  2. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
  3. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
  4. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799 ]
  5. Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c. [PubMed:19151602 ]
  2. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351 ]
  3. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  2. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  2. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  3. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
  2. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y: Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 Oct;25(10):1123-9. [PubMed:9321514 ]
  3. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002 Feb 22;277(8):6497-503. Epub 2001 Dec 17. [PubMed:11748225 ]
  4. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:
SLC16A1
Uniprot ID:
P53985
Molecular Weight:
53943.685 Da
References
  1. Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A: Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995 Nov;12(11):1727-32. [PubMed:8592677 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Morisawa Y, Takikawa H: Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol Res. 2009 Jun;39(6):595-600. doi: 10.1111/j.1872-034X.2009.00493.x. Epub 2009 Feb 24. [PubMed:19260999 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Link [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23